Abbott unveils name for new pharma company; Motley Fool contributor blasts Read's pay increase;

 @FiercePharma: Pfizer to pay $3.3M to settle Zyvox probe. Story | Follow @FiercePharma

> Abbott Labs ($ABT) has announced the name of the independent pharmaceutical company it expects to launch by the end of the year: AbbVie. Its logo will be revealed upon launch. News

> In a commentary, The Motley Fool's Sean Williams takes aim at Pfizer ($PFE) CEO Ian Read's 44% pay raise. Commentary

> Janssen's Psoriasis 360 page on Facebook is closing down. The company was increasingly having to remove comments because specific drugs were mentioned and users were writing offensive posts. More

> Canadian regulators have given their blessing to Paladin Labs' oral drug to treat seasonal grass allergies. The company expects to launch the drug, Oralair, in 2013. Item

> GE Healthcare ($GE) will unveil roughly 20 new products to be developed in India this year. The company spends about $50 million on R&D there annually--and it's finally seeing results, Forbes notes. Story

Biotech News

 @FierceBiotech: Cytos revives lead program in $40M financing deal with Amgen, venBio. News | Follow @FierceBiotech

 @JohnCFierce: NicOx (France) takes an option to buy Altacor in the U.K., with an eye to building an opthalmology co. Release | Follow @JohnCFierce

 @RyanMFierce: Hepatera, a Russian biotech, has grabbed a mystery amount of funding for a hepatitis program. Release | Follow @RyanMFierce

@FierceMedDev: Stryker Stent May Not Be Worth the Stroke Risks, FDA Says via @BloombergNews. Story | Follow @FierceMedDev

> GSK, J&J back Index's new $200M fund for early-stage deals. News

> FDA panel shoots down Merck/Ariad cancer drug as GSK marches on. Story

> NicOx eyes global status in eye drug game with up to $30.9M buyout of Altacor. Article

Medical Device News

> Olympus confronts scandal with 3 new surgical devices. News

> U.S. Supreme Court KO's Prometheus Labs' test patent suit. More

> Genoptix test to guide melanoma treatment decisions. Story

> J&J lawsuit bombshell: Company marketed vaginal mesh minus FDA nod. Article

Biomarkers News

> There may be more to mesothelioma than mesothelin. Item

> RNA could predict cancer recurrence risk. Article

> Triple-negative breast cancer biomarker points to new cancer model. More

> Study: Alzheimer's not prevented by antioxidants. Story

Drug Delivery News

> Bend Research, in nod to Pfizer, eyes biotherapeutics drug delivery. Story

> Echo Therapeutics reports $16.7M loss after Prelude delay. More

> U.K. CF gene therapy trials to test inhaled and viral delivery options. Article

And Finally... Regardless of gender, people who took a daily dose of aspirin had a 24% lower rate of developing cancer after three years and were 37% less likely to die from the disease after 5 years versus those who didn't, a study shows. News